South San Francisco-based biotechnology company Exelixis Inc. (EXEL) said it has netted approximately $71.8 million through its public offering of 7 million shares of common stock.
Underwriter Goldman, Sachs & Co. has also been granted a 30-day option to purchase up to an additional 1.05 million shares of common stock.
businessBusiness & Real Estate
Find out more at www.sfexaminer.com/join/